Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 87 for “"BRAFV600E"”.
-
In sillico μελέτες αναστολέων της μεταλλαγμένης ογκοπρωτεΐνης BRAFV600E
… και ο καρκίνος των ωοθηκών (~30%). Η μετάλλαξη BRAFV600E είναι η πιο συχνή μετάλλαξη οδηγώντας σε υπερενεργοποίηση του μονοπατιού και σε καρκινογένεση. Το Vemurafenib (Zelboraf) και το Dabrafenib (Tafinlar) αποτελούν τα δύο εγκεκριμένα φάρμακα, εκλεκτικοί αναστολείς της BRAFV600E που χορηγούνται …
-
DEVELOPING NOVEL THERAPEUTIC STRATEGIES FOR mCRC WITH A BRAFV600E MUTATION
… in CRC. The most common BRAF mutation is BRAFV600E, which occurs in 10-15% of CRC cases. The BRAFV600E mutation usually occurs early in tumorigenesis and is associated with an aggressive phenotype and poorer patient outcomes, potentially resulting from constitutive MAPK signaling and …
-
Leveraging copper chelators as targeted therapy for BRAFV600E mutant thyroid cancer
… and thus may find use in long-term inhibition of BRAFV600E signaling in PTC. </p><p>Here I test the ability of Cu chelator TM to inhibit tumor growth in BRAFV600E-mutant PTC. TM inhibited MEK1/2 kinase activity and transformed growth of human BRAFV600E-mutant PTC cells as well as or more potently …
-
Zebrafish as a model of BRAFV600E melanoma subtypes and Nevus biology
… how additional mutations co-operate with BRAFV600E to promote subtypes of melanoma in animals is only beginning to be understood. In this thesis, I generate and analyze zebrafish BRAFV600E melanoma models and also develop the first animal model for BRAFV600E nevus recurrence. In my first …
-
Epigenetic Modification as a Therapeutic Target in BRAFV600E-mutated Metastatic Colorectal Cancer
Patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) experience a worse prognosis and demonstrate only a 5% response rate to BRAF inhibitor treatment. In this study, adaptive resistance, and a potential combination of standard therapies in BRAFV600E CRC were unveiled. Intriguingly, a …
-
Εικονική σάρωση βιβλιοθηκών για τον προσδιορισμό νέων αναστολέων της μεταλλαγμένης ογκοπρωτεϊνης BRAFV600E
… μελανώματος που φέρει τη μετάλλαξη BRAFV600E, όμως η αποτελεσματικότητά τους είναι περιορισμένη λόγω ανάπτυξης ανθεκτικότητας καθώς και της παράδοξης ενεργοποίησης του μονοπατιού ΜΑΡΚ σε wt-BRAF κύτταρα, που οδηγεί σε ογκογένεση. Tα PLX7904 και PLX8394 (Paradox breakers) αποτελούν …
-
Development And Characterization Of Novel Raf Dimer Inhibitors To Target Brafv600e Inhibitor Resistance
… a single V600E activation segment mutation (BRAFV600E) accounts for ~90% of BRAF mutant malignant tumors. BRAFV600E selective inhibitors, such as vemurafenib, extend the survival of patients in the clinic, however most patients develop drug resistance and progress at a median of 6 months. One …
-
SINGLE-STEP INDUCTION OF RIGHT-SIDED COLON CANCER PHENOTYPE BY BRAFV600E THROUGH ACQUIRED WNT ACTIVATION
… carcinogenesis of colorectal cancer by inducing BRAFV600E and KRASG12D individually in organoids prepared from mouse proximal colon and subsequently determined the genome-wide gene expression, DNA methylation, and genetic changes in combination with growth properties and induction of tumor …
-
Modulation of BRAFV600E Signalling in Melanoma and Colorectal Cancer: Consequences for Tumour Immune Cell Infiltration
… BRAF containing the V600E mutation (BRAFV600E) is present in 50% of melanomas and 10% of colorectal cancers (CRCs), spurring the development of small-molecule BRAFV600E inhibitors. These compounds are initially effective in treatment of advanced melanoma, the most responsive tumour …
-
Relation between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer
PURPOSE: BRAFV600E mutation and F-18 fluorodeoxyglucose (FDG) uptake are potential prognostic factors of papillary thyroid cancer (PTC). This study was performed to investigate the relationship between the BRAFV600E mutation and F-18 FDG uptake in PTC. MATERIALS AND METHODS: We retrospectively …
-
«Επιλεκτικοί αναστολείς της ογκοπρωτεΐνης BRAFV600E μέσω ανάλυσης χημικής ομοιότητας, in silico μελέτες πρόσδεσης και in vitro έλεγχο»
… από τον FDA εκλεκτικούς αναστολείς της BRAFV600E, οι οποίοι έχουν βελτιώσει σημαντικά την επιβίωση των ασθενών προχωρημένου σταδίου μελανώματος. Η μονοθεραπεία με τους BRAFV600E αναστολείς επάγει δευτερογενή νεοπλάσματα, εξαιτίας της παράδοξης ενεργοποίησης του MAPK μονοπατιού που …
-
A functional dissection of the relationships between BRAF, DNMT3B and the CpG island methylator phenotype in colorectal cancer
… human colorectal cancers harbour an activating BRAFV600E mutation, which acts as a founder mutation for an alternative, serrated pathway of colorectal carcinogenesis. Conversely, BRAFV600E mutations are detectable in hyperplastic colonic polyps: lesions traditionally considered not to harbour …
-
Μελέτη των σηματοδοτικών οδών BRAF/MEK/ERK και AKT/mTOR στη λευχαιμία εκ τριχωτών κυττάρων
Introduction: BRAFV600E has been proven the molecular hallmark in Hairy Cell Leukemia (HCL) lymphomagenesis. ΑΚΤ/mTOR pathway plays critical role in cell proliferation, differentiation and migration and is interconnected with MAPK signalling in several points. This study investigates for the first …
-
Targeted RAS pathway inhibitors and their rational combinations can sensitise resistant cancer cells to apoptosis
… - εγκεκριμένοι από το FDA αναστολείς της BRAFV600E μεταλλαγμένης κινάσης-ογκοπρωτεΐνης-, είναι αποτελεσματικά στη θεραπεία του BRAF μεταλλαγμένου μελανώματος, οι νεοπλασίες παχέος εντέρου με BRAF μετάλλαξη παρουσιάζουν ανθεκτικότητα στις παραπάνω θεραπείες που στοχεύουν το BRAFV600Ε. Η …
-
Expression of X-linked Inhibitor of Apoptosis Protein in Neoplastic Thyroid Disorder
… the association of XIAP expression and the BRAFV600E mutation and analyzed the association of XIAP expression and tumor recurrence in BRAFV600E prevalent PTC population. Expression of XIAP was evaluated with immunohistochemical staining using monoclonal anti-XIAP in 164 specimens of …
-
Understanding the Genetic Basis of Immune Responses to Enterotoxigenic Bacteroides fragilis Infection
… mutation in the MAPK signaling component BRAF (BRAFV600E) display a striking accumulation of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. The addition of BRAFV600E, but not a closely related activating mutation in the MAPK pathway KrasG12D, to the ApcMin/+ model …
-
Γονιδιακή έκφραση σε κυτταρικά μοντέλα σποραδικού καρκίνου του παχέος εντέρου (ΚΠΕ) επαγόμενη από τις ογκοπρωτεΐνες K - RAS και B - RAF
… it was investigated the effect of oncogenes BRAFV600E and KRASG12V in sporadic colorectal cancer. It was studied the transformation of human intermediate adenoma colon cells (Caco-2) by these two oncogenes and their effect on cytoskeletal properties of cells through Rho GTPases. A model of …
-
Morphologische Charakterisierung der BRAF mutierten Melanome mittels Immunhistochemie, Dermatoskopie und konfokaler Laserscanmikroskopie
… distinguished based on genetic mutations such as BRAFV600E, corresponding morphological patterns might be hypothesized. Aim of this study was to further characterize BRAF mutated melanomas compared to their wild type counterpart based on alternative methods such as in-vivo confocal microscopy …
Page 1 of 5